Can broader diffusion of value-based insurance design increase benefits from us health care without increasing costs? Evidence from a computer simulation model

PLoS Medicine

Volumn 7, Issue 2, 2010, Pages

  Braithwaite, R Scott ^a   Omokaro, Cynthia ^b   Justice, Amy C ^c   Nucifora, Kimberly ^a   Roberts, Mark S ^d,e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER SIMULATION; HEALTH CARE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; LIFE EXPECTANCY; PHARMACY; UNITED STATES; COST; ECONOMICS; HUMAN; THEORETICAL MODEL;

COMPUTER SIMULATION; COST SHARING; HUMANS; INSURANCE, HEALTH; MODELS, THEORETICAL; UNITED STATES;

EID: 77649092135     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000234     Document Type: Article

References (25)

1. Newhouse JP (1993) An iconoclastic view of health cost containment. Health Affairs (Millwood) 12(Suppl): 152-171.
2. Goldman DP, Joyce GF, Zheng Y (2007) Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298: 61-69.
3. Kaiser Family Foundation and Health Research and Educational Trust. Employer Health Benefits, 2007 summary of findings. Menlo Park (California): Henry J. Kaiser Family Foundation.
4. Trivedi AN, Rakowski W, Ayanian JZ (2008) Effect of cost sharing on screening mammography in medicare health plans. N Engl J Med 358: 375-383.
5. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, et al. (2008) Impact of decreasing copayments on medication adherence within a disease management environment. Health Affairs (Millwood) 27: 103-112.
6. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, et al. (2005) Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 143: 89-99.
7. Fendrick AM, Smith DG, Chernew ME, Shah SN (2001) A benefit-based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 7: 861-867.
8. Chernew ME, Rosen AB, Fendrick AM (2007) Value-based insurance design. Health Aff (Millwood) 26: w195-203.
9. Braithwaite RS, Rosen AB (2007) Linking cost sharing to value: An unrivaled yet unrealized public health opportunity. Ann Intern Med 146: 602-605.
10. Neumann PJ, Rosen AB, Weinstein MC (2005) Medicare and cost-effectiveness analysis. N Engl J Med 353: 1516-1522.
11. Lambrew JM (2008) Testimony for the hearing "Getting Better Value in Health Care." Testimony before the Committee on the Budget, US House of Representatives 16 July 2008. Available: http://budget.house.gov/hearings/ 2008/07.16lambrew.pdf. Accessed 08 September 2009.
12. Mahoney JJ (2005) Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 11(5 Suppl): S170-176.
13. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS (2008) What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46: 349-356.
14. Devlin N, Parkin D (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13: 437-452.
15. Ubel PA, Hirth RA, Chernew ME, Fendrick AM (2003) What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163: 1637-1641.
16. Meara E, White C, Cutler DM (2004) Trends in medical spending by age, 1963-2000. Health Aff (Millwood) 23: 176-183.
17. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, et al. (2000) Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132: 769-779.
18. Pignone M, Earnshaw S, Tice JA, Pletcher MJ (2006) Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med 144: 326-336.
19. Goldman DP, Joyce GF, Karaca-Mandic P (2006) Varying pharmacy benefits with clinical status: The case of cholesterol-lowering therapy. Am J Manag Care 12: 21-28.
20. Braithwaite RS, Roberts MS, Justice AC (2007) Incorporating quality of evidence into decision analytic modeling. Ann Intern Med 146: 133-141.
21. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, et al. (2003) The implications of regional variations in medicare spending. part 2: Health outcomes and satisfaction with care. Ann Intern Med 138: 288-298.
22. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-Effectiveness in Health and Medicine. New York (New York): Oxford University Press.
23. Newhouse JP (1993) Free for All? Lessons from the RAND Health Experiment. Cambridge (Massachusetts): Harvard University Press.
24. Cherkin DC, Grothaus L, Wagner EH (1989) The effect of office visit copayments on utilization in a health maintenance organization. Med Care 27(11): 1036-1045.
25. Selby JV, Fireman BH, Swain BE (1996) Effect of a copayment on use of the emergency department in a health maintenance organization. N Engl J Med 334: 635-641.